Linda Palczuk - Net Worth and Insider Trading

Linda Palczuk Net Worth

The estimated net worth of Linda Palczuk is at least $1 Million dollars as of 2024-05-04. Linda Palczuk is the Director of Avadel Pharmaceuticals PLC and owns about 52,400 shares of Avadel Pharmaceuticals PLC (AVDL) stock worth over $986,168. Linda Palczuk is also the COO of Verrica Pharmaceuticals Inc and owns about 8,500 shares of Verrica Pharmaceuticals Inc (VRCA) stock worth over $61,710. Details can be seen in Linda Palczuk's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Linda Palczuk has not made any transactions after 2023-05-09 and currently still holds the listed stock(s).

Transaction Summary of Linda Palczuk

To

Linda Palczuk Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Linda Palczuk owns 3 companies in total, including Avadel Pharmaceuticals PLC (AVDL) , Verrica Pharmaceuticals Inc (VRCA) , and Osiris Therapeutics Inc (OSIR) .

Click here to see the complete history of Linda Palczuk’s form 4 insider trades.

Insider Ownership Summary of Linda Palczuk

Ticker Comapny Transaction Date Type of Owner
AVDL Avadel Pharmaceuticals PLC 2023-05-09 director
VRCA Verrica Pharmaceuticals Inc 2019-01-16 Chief Operating Officer
OSIR Osiris Therapeutics Inc 2017-07-10 President & CEO

Linda Palczuk Latest Holdings Summary

Linda Palczuk currently owns a total of 2 stocks. Among these stocks, Linda Palczuk owns 52,400 shares of Avadel Pharmaceuticals PLC (AVDL) as of May 9, 2023, with a value of $986,168 and a weighting of 94.11%. Linda Palczuk also owns 8,500 shares of Verrica Pharmaceuticals Inc (VRCA) as of January 16, 2019, with a value of $61,710 and a weighting of 5.89%.

Latest Holdings of Linda Palczuk

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AVDL Avadel Pharmaceuticals PLC 2023-05-09 52,400 18.82 986,168
VRCA Verrica Pharmaceuticals Inc 2019-01-16 8,500 7.26 61,710

Holding Weightings of Linda Palczuk


Linda Palczuk Form 4 Trading Tracker

According to the SEC Form 4 filings, Linda Palczuk has made a total of 5 transactions in Avadel Pharmaceuticals PLC (AVDL) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Avadel Pharmaceuticals PLC is the acquisition of 2,500 shares on May 9, 2023, which cost Linda Palczuk around $36,900.

According to the SEC Form 4 filings, Linda Palczuk has made a total of 0 transactions in Verrica Pharmaceuticals Inc (VRCA) over the past 5 years. The most-recent trade in Verrica Pharmaceuticals Inc is the acquisition of 3,000 shares on January 16, 2019, which cost Linda Palczuk around $31,590.

Insider Trading History of Linda Palczuk

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Linda Palczuk Trading Performance

GuruFocus tracks the stock performance after each of Linda Palczuk's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Linda Palczuk is 23.54%. GuruFocus also compares Linda Palczuk's trading performance to market benchmark return within the same time period. The performance of stocks bought by Linda Palczuk within 3 months outperforms 3 times out of 8 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Linda Palczuk's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Linda Palczuk

Average Return

Average return per transaction

Outperforming Transactions

6 out of 8 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.75
Relative Return to S&P 500(%) -3.31

Linda Palczuk Ownership Network

Ownership Network List of Linda Palczuk

No Data

Ownership Network Relation of Linda Palczuk


Linda Palczuk Owned Company Details

What does Avadel Pharmaceuticals PLC do?

Who are the key executives at Avadel Pharmaceuticals PLC?

Linda Palczuk is the director of Avadel Pharmaceuticals PLC. Other key executives at Avadel Pharmaceuticals PLC include Chief Financial Officer Thomas S Mchugh , director & Chief Executive Officer Greg J Divis , and Chief Commercial Officer Richard J Kim .

Avadel Pharmaceuticals PLC (AVDL) Insider Trades Summary

Over the past 18 months, Linda Palczuk made 2 insider transaction in Avadel Pharmaceuticals PLC (AVDL) with a net purchase of 4,500. Other recent insider transactions involving Avadel Pharmaceuticals PLC (AVDL) include a net purchase of 9,000 shares made by Thomas S Mchugh , a net sale of 103,975 shares made by Mark Anthony Mccamish , and a net purchase of 33,000 shares made by Eric J Ende .

In summary, during the past 3 months, insiders sold 0 shares of Avadel Pharmaceuticals PLC (AVDL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 103,975 shares of Avadel Pharmaceuticals PLC (AVDL) were sold and 70,500 shares were bought by its insiders, resulting in a net sale of 33,475 shares.

Avadel Pharmaceuticals PLC (AVDL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Avadel Pharmaceuticals PLC Insider Transactions

No Available Data

Linda Palczuk Mailing Address

Above is the net worth, insider trading, and ownership report for Linda Palczuk. You might contact Linda Palczuk via mailing address: 7015 Albert Einstein Drive, Columbia Md 21046.

Discussions on Linda Palczuk

No discussions yet.